BioTime CEO Dr. Michael West Presents at European Stem Cells & Regenerative Medicine Congress 2008

Business Wire, May 15, 2008

ALAMEDA, Calif. -- BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, PhD gave a presentation at the European Stem Cells & Regenerative Medicine Congress 2008 being held May 13-15 in London, United Kingdom. This year's conference theme is "Transform - Translating stem cell research from bench to business."

The title of Dr. West's presentation was "Mapping the human embryome: multiplex strategies for the purification and characterization of human embryonic progenitor cells" in a session focused on the expansion of clinical automation processes in the stem cell industry.

The 3rd annual European Stem Cells & Regenerative Medicine Congress is focused on bridging the gaps between researchers, investors, and manufacturers in the expanding global market for stem cell products and services at a time when stem cell research continues to make significant advances towards valuable medical treatments.

Dr. West's presentation included a description of BioTime's programs in the stem cell area that are focused on opportunities for near-term revenues in the marketing of cell lines, growth and differentiation factors, and antibodies through a relational database and research tool called Embryome.com.

The keynote presentations were by Dr. Alan Trounson, President of the California Institute of Regenerative Medicine and Bernard Siegel, Executive Director of the Genetics Policy Institute.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc., through which it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend([R]), PentaLyte([R]), HetaCool([R]), Embryomics(TM), ESpy(TM), and EScalate(TM) are trademarks of BioTime, Inc.

Forward Looking Statements

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.

Click here to join our email alert list.